Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on CNS Therapeutics. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN101874016A details a scalable mesylate-based route for CNS drug intermediates, offering superior purity and cost-effective manufacturing solutions.
Patent CN105793263A details a scalable synthesis for ASD intermediates. Discover cost reduction in API manufacturing and high-purity pharmaceutical intermediates supply.
Patent CN112708641A discloses a high-efficiency chemo-enzymatic route for tomoxetine. Achieves >99.9% ee and high substrate loading for cost-effective manufacturing.
Advanced DMSO/HBr cyclization method for high-purity benzothiazole intermediates. Reduces cost and improves scalability for adenosine receptor ligand manufacturing.
Patent CN1132202A discloses selective sigma receptor ligands with reduced CNS side effects, offering scalable synthesis routes for high-purity pharmaceutical intermediates.
Advanced synthesis of 3-benzazepines via novel cyclization and reduction routes. Offers cost reduction in API manufacturing and scalable production for CNS disorder treatments.
Discover a cost-effective synthesis of ganaxolone via direct methylation. Enhanced purity and supply chain reliability for pharmaceutical intermediates.
Advanced anhydrous synthesis of Aripiprazole Lauroxil via paraformaldehyde. Delivers high-purity antipsychotic prodrugs with improved yields and cost reduction in API manufacturing.